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ABSTRACT
Introduction: The mitochondrial DNA A3243G point
mutation is associated with a wide variety of systemic
manifestations including a macular dystrophy. The
characteristics of fundus autofluorescence (AF) in these
patients are distinctive and have not been previously
described.
Methods: A complete history and ophthalmic examina-
tion, including fundus photography and autofluorescence
imaging, was performed on twelve probands harbouring
the A3243G point mutation.
Results: Four patients had diabetes, 10/12 hearing loss,
and 7/12 were visually symptomatic. A positive family
history was present in 5/12. Fundus findings consisted of
two primary phenotypes: discontinuous circumferentially
oriented perifoveal atrophy (9/12) or an appearance
consistent with pattern dystrophy (3/12). In both
phenotypes pale deposits and pigment clumping were
seen at the level of the retinal pigment epithelium, with
occasional changes also noted outside the arcades and
nasal to the optic nerve. Fundus AF imaging revealed
decreased autofluorescence in areas of atrophy and
increased AF of the pale subretinal deposits. In areas of
the retina that appeared normal clinically, variable sized
flecks of increased and decreased AF were present.
Conclusions: The mitochondrial DNA A3243G point
mutation can result in disease with a variable presenta-
tion. Fundus autofluorescence reveals a recognisable
phenotype in most cases that is different from other
macular dystrophies.
The single-point mutation of the mitochondrial
DNA (mtDNA) at the 3243 position in the
tRNA
Leu(UUR) gene leads to a wide variety of clinical
manifestations. This mutation was originally
described in association with Mitochondrial
Encephalopathy, Lactic Acidosis and Stroke-like
episodes (MELAS), and is now known to produce a
variety of other clinical disorders, including mater-
nally inherited diabetes and deafness (MIDD),
cardiomyopathy, chronic progressive external
ophthalmoplegia (CPEO), a pure myopathy, gas-
trointestinal dysmotility and renal failure.
1–6 One
explanation for this variability is thought to be the
load of mutant mtDNA present in an individual,
which varies both between individuals and from
tissue to tissue within an individual.
7 In general, a
higher mutation load is associated with more
severe disease. However, this generalisation does
not always hold true, and it is possible that
environmental factors and/or nuclear genetic
influences may modulate disease manifesta-
tions.
689
Ocular manifestations of mitochondrial diseases
are well recognised, and in the original report by
Reardon et al which revealed a new subtype of
diabetes caused by a mtDNA mutation, three
patients were found to have retinal pigmentary
changes.
21 0However, there were no fundus photo-
graphs of the changes described in this initial
report.
2 In 1995, Massin et al described the
association of a bilateral macular pattern dystro-
phy with MIDD and further characterised this in a
subsequent publication in 1999.
11 12 Since these
reports, there have been several additional publica-
tions describing the macular dystrophy of MIDD
and MELAS, both clinically and electrophysiologi-
cally.
13–18
The use of the confocal scanning laser ophthal-
moscope (cSLO) for imaging of macular diseases
has been well described.
19–25 In this study, we have
characterised in detail the distinct fundus auto-
fluorescence (AF) characteristics of the macular
dystrophy associated with the A3243G mtDNA
mutation.
METHODS
All patients diagnosed as having a macular
dystrophy due to the A3243G mtDNA mutation
in the Medical Retina Clinic at Moorfields Eye
Hospital between 1995 and 2001 were included in
the study. Twelve patients in total were evaluated.
Patient demographics, referring diagnosis, presence
or absence of visual symptoms, duration of visual
symptoms, general medical history including pre-
sence or absence of diabetes and deafness, maternal
history of diabetes and deafness, and a detailed
family history, were obtained for each patient.
Best-corrected Snellen visual acuity and slit-lamp
biomicroscopy findings were recorded. Colour
fundus photographs and fundus autofluorescence
imaging were performed. Patients were tested for
the A3243G mutation based on the characteristics
of their ophthalmic examination, regardless of
whether or not there was a personal or family
history of diabetes or deafness. The diagnosis of
the A3243G mtDNA mutation was established
with DNA testing of peripheral blood samples
using previously described techniques.
26
Fundus autofluorescence imaging was performed
with a confocal scanning laser ophthalmoscope
(cSLO, Zeiss, Jena, Germany or HRA, Heidelberg,
Germany) using previously published techni-
ques.
19 20 27 Autofluorescence images were compared
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the A3243G mutation were also compared with images of
patients with other maculopathies, including Stargardt macular
dystrophy, R172W peripherin macular dystrophy, bull’s eye
macular dystrophy, geographic atrophy from age-related macular
degeneration and pattern dystrophy.
Patients who did not have a history of diabetes were tested
with fasting blood glucose, where possible, according to the
recommendations of the American Diabetic Association.
28 Renal
function tests were also performed when possible due to the
association of renal dysfunction with the A3243G mutation.
29
RESULTS
Twelve patients were diagnosed as having the A3243G
mutation between January 1995 and February 2001; in none
had the diagnosis of a mitochondrial disorder been made prior to
being seen by the authors. The characteristics of these patients
at presentation are summarised in table 1.
Nine of the patients were female. The average age at
presentation was 47 years (range 36 to 65) with an average
age at diagnosis of 51 (range 36 to 71). In six of 12 patients, the
reason for referral to a specialist clinic was an unspecified
maculopathy consisting of a combination of retinal pigment
epithelial changes and atrophy. Other diagnoses at referral were
Usher syndrome variant, central areolar choroidal sclerosis,
pattern dystrophy, macular degeneration and macular atrophy.
Five of the 12 patients did not have visual symptoms at
presentation and were found to have fundus abnormalities on
routine eye examination. Of the patients who were initially
asymptomatic, two patients became symptomatic during
review. Three patients are still asymptomatic after follow-up,
ranging from 1 to 6 years. Asymptomatic patients tended to be
younger than the patients with symptoms, with a mean age of
43 compared with 51 years of age, although the number of
patients in each group is too small for statistical significance to
be established. Of the seven patients with symptoms, three
reported difficulties due to paracentral scotoma, and three
reported a general decrease in vision in one eye.
A history of hearing loss was common, with 10 of 12 patients
having some degree of hearing impairment. Patient 1 had a
cochlear implant, and four other patients were using hearing
aids. Diabetes was present in only four patients, all of whom
also had hearing loss.
A maternal history of diabetes was present in two patients
and a maternal history of deafness in five patients. A maternal
history of both diabetes and deafness was elicited in only one
subject. There were two additional patients with a maternal
history of hearing loss diagnosed after the age of 75 years. This
was considered to be age-related hearing loss and not included
as a positive history in the context of a mitochondrial disease.
Two further patients had a family history of maternal diabetes,
which was not diagnosed until the age of 60, and was again not
considered as a positive finding in the context of the A3243G
mutation.
In all patients, presenting visual acuity was good, each having
at least 6/9 or better vision, and seven patients achieving 6/6 or
better vision, with each eye. At final follow-up, the vision was
slightly worse, with all patients having 6/12 or better vision in
at least one eye. Six out of 12 patients had 6/6 or better vision
with at least one eye at the last documented examination. Of
the four patients with 6/12 or worse vision, three had
deterioration in vision due to paramacular atrophy encroaching
upon fixation, and one had decreased vision bilaterally due to
retinal pigment epitheliopathy.
The fundus appearance was variable between patients, but
two separate phenotypes were identified. The most common
phenotype, occurring in nine of the 12 patients, was discontin-
uous perifoveal atrophy that was circumferentially distributed
and oriented (fig 1). In patients who had follow-up over many
years, the atrophy coalesced into a ring (fig 2). The central fovea
was spared in all but one eye of a single patient (fig 3). Adjacent
to the areas of atrophy were pale deposits at the level of the
retinal pigment epithelium (RPE), granularity of the RPE and
subretinal pigment clumping. The second phenotype, present in
three patients, was an appearance consistent with a pattern
dystrophy. In these three patients, no significant atrophy was
present in the perifoveal area. There was granularity of the RPE
and pale deposits and pigment clumping at the level of the RPE
(fig 4). The majority of the fundus changes occurred within the
temporal vascular arcades; however, RPE changes were also seen
outside the arcades and nasal to the optic nerve.
The appearance on fundus autofluorescence (AF) imaging
was of a diffuse macular abnormality. Decreased AF was present
in areas of atrophy, and the pale deposits revealed increased AF.
In the more common perifoveal atrophy phenotype, the retina
surrounding the atrophic areas demonstrated speckled AF (figs 1,
3, 5). In the pattern dystrophy phenotype, there was a diffuse
Table 1 Maternally inherited diabetes and deafness patient characteristics at presentation





1 F 48 Usher No Yes Yes No No*
2 F 42 Central areolar choroidal sclerosis Yes No No No{ No
3 F 53 Non-specific maculopathy Yes No Yes No Yes
4 F 47 Non-specific maculopathy Yes No Yes No Yes
5 F 36 Non-specific maculopathy Yes No Yes Yes No
6 M 65 Non-specific maculopathy Yes No Yes No No*
7 F 43 Pattern dystrophy No No Yes ? ?
8 M 43 Macular degeneration Yes Yes Yes No{ No
9 F 38 Non-specific maculopathy Yes No Yes No No
10 F 55 Stargardt versus mitochondrial No No Yes No Yes
11 F 48 Macular atrophy No Yes No Yes Yes
12 M 46 Non-specific maculopathy No Yes Yes No Yes
Total 7/12 4/12 10/12 2/12 5/12
*Hearing loss diagnosed after the age of 75; patients 3 and 4 are a mother and daughter, and ages are at presentation of disease.
{Adult onset DM diagnosed at age 60.
Clinical science
624 Br J Ophthalmol 2008;92:623–629. doi:10.1136/bjo.2007.131177Figure 1 (A, B) Fundus photographs of
patient 1 showing circumferential
orientation and distribution of the
discontinuous perifoveal atrophy. (C, D)
Fundus AF images of patient 1
demonstrating decreased AF of the areas
corresponding to chorioretinal atrophy
and speckled AF surrounding the areas of
atrophy. There is abnormal AF nasal to
the optic nerve and just outside the
superior temporal vascular arcade.
Patient consent has been obtained for
publication of this figure.
Figure 2 (A, B) Fundus photographs of
patient 8 taken in 1994 showing
circumferential distribution of the
perifoveal atrophy. (C, D) Fundus
photographs of patient 8 taken in 2001
showing that the atrophy has coalesced
almost to a complete ring with central
foveolar sparing. Patient consent has
been obtained for publication of this
figure.
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case was the diffuse nature of the abnormality evident on
biomicroscopy.
DISCUSSION
The characteristics of AF associated with the A3243G mtDNA
mutation are distinct and differ from the majority of other
macular dystrophies. In Stargardt macular dystrophy (STGD),
well-defined atrophy is associated with diminished AF and the
flecks with increased AF. The intervening retina has homo-
geneous AF. Figure 7A,B shows AF imaging of a male with
typical fundus findings of STGD. In pattern dystrophy, as with
STGD, the areas of abnormal AF are limited to abnormal areas
detectable by ophthalmoscopy. In geographic atrophy (GA) due
to age-related macular degeneration (AMD), the atrophic area is
associated with decreased AF and may have a rim of increased
AF as described by Holz et al (fig 8).
20 In each of these
conditions, the AF abnormalities correlate with the funduscopic
abnormalities, and there is no widespread speckled AF, as
observed with the A3243G mtDNA mutation. In the latter, it is
not only the area of clinically detectable disturbance that is
abnormal; indeed the area of abnormal AF is significantly larger
than would be expected from the funduscopic appearance.
Perhaps the most difficult macular dystrophy to distinguish
from that associated with the A3243G mtDNA mutation, by AF
imaging alone, is the maculopathy caused by the dominant
R172W peripherin mutation. The AF imaging in patients with
the R172W mutation has been previously described and appears
to depend on the stage of the disease.
21 In the early symptomatic
stages, these patients have a diffuse macular abnormality on AF
consisting of speckled areas of increased and decreased AF
within the macula simulating the pattern dystrophy-like
phenotype of the A3243G mtDNA mutation. Later areas of
atrophy develop within the areas of abnormal autofluorescence
although not in the circular pattern seen in the patients with
the mitochondrial dystrophy in this series. In addition, unlike
A3243G maculopathy, the changes seen in R172W patients
appear to be confined to the macular and peripapillary regions
until very late in the disease when atrophic changes can extend
beyond the arcades (fig 9).
Figure 3 (A, B) Fundus photograph and
AF image of patient 9 showing a large
area of central atrophy corresponding to
the decreased AF. There is extensive
speckled AF surrounding the atrophy. This
is the only patient who lost fixation due to
progression of atrophic changes. Patient
consent has been obtained for publication
of this figure.
Figure 4 (A, B) Fundus photographs of
patient 10 showing a granular appearance
to the RPE. The yellow-white deposits at
the level of the RPE are circumferentially
oriented and extend just beyond the
vascular arcades. The deposits are
slightly more prominent in the left eye. In
the right eye, there is a small circular
patch of perifoveal atrophy present
superiorly. (C, D) Fundus AF images of
patient 10, 2 years after the fundus
photographs. The pale yellow deposits
are associated with increased AF oriented
in a circular fashion surrounding the
macula and optic nerve. There is
decreased AF in areas of atrophy and a
diffuse abnormality of AF within the
macula and surrounding the optic nerve,
which is greater than expected, based on
the fundus photographs. Patient consent
has been obtained for publication of this
figure.
Clinical science
626 Br J Ophthalmol 2008;92:623–629. doi:10.1136/bjo.2007.131177Figure 5 (A, B) Fundus photograph and
AF image of patient 11. The areas of
decreased AF correspond to the atrophy,
which is circumferentially oriented and
surrounded by irregular increased AF.
Patient consent has been obtained for
publication of this figure.
Figure 6 (A, B) Fundus photograph and
AF image of patient 7. Note the diffuse
abnormality of the macular AF
demonstrated by speckled AF which is
much greater than would be expected
based on the fundus photograph. Patient
consent has been obtained for publication
of this figure.
Figure 7 (A, B) AF images of Stargardt
macular dystrophy. Note the areas of
atrophy are within the fovea
corresponding to decreased AF. There are
surrounding areas of increased AF
corresponding to the pale yellow flecks
seen in STGD; between the flecks and
atrophy, there is normal AF. Patient
consent has been obtained for publication
of this figure.
Figure 8 (A, B) AF images of
geographic atrophy in age-related
macular degeneration. The central areas
of atrophy show decreased AF with a
surrounding rim of increased AF. Patient
consent has been obtained for publication
of this figure.
Clinical science
Br J Ophthalmol 2008;92:623–629. doi:10.1136/bjo.2007.131177 627The estimated prevalence of the A3243G mtDNA mutation
resulting in MIDD in the diabetic population varies between
0.13 and 2.8%.
30–38 In a recent multi-centre study, the systemic
manifestations of MIDD in patients with diabetes were
recorded in order to ascertain patients with diabetes who
would benefit from screening for mitochondrial mutations.
29 All
patients included in this study had diabetes, 98% had bilateral
neurosensory hearing loss, and 87% had macular pattern
dystrophy. The percentage of patients with diabetes and
deafness in this group was very high, as would be expected,
given that patients were enrolled in the study based on these
traits. In general, patients with the A3243G mtDNA mutation
have a variety of disease manifestations including MIDD.
5 6 39–41
Patients with macular dystrophy associated with the A3243G
mutation diagnosed from an ophthalmology clinic may have
more variable systemic manifestations than patients ascertained
based on the presence of diabetes and deafness. In our small
cohort of patients who presented with macular dystrophy, 83%
(10/12) had symptomatic hearing loss, while only 33% (4/12)
had diabetes. None of the patients in this series had diabetes
without hearing loss. In addition, all patients in this series were
diagnosed by the ophthalmologist as having a mitochondrial
macular dystrophy, which was confirmed by testing for the
A3243G mutation.
A potential weakness of this paper is the fact that only
patients positive for the mitochondrial DNA mutation were
included in the study. Although some patients were probably
tested for the mutation and found to be negative, those patients
were not included in this analysis. Therefore, we do not know
the number of patients seen during the study period with a
similar clinical phenotype who were negative for the A3243G
mutation. Additionally, we assume the AF pattern we describe
would be the same in all patients with a macular dystrophy
secondary to the A3243G mutation. But because all of our
patients were seen in an ophthalmology clinic, it might be
interesting to perform a similar study on a population of
diabetics known to have the A3243G mitochondrial DNA
mutation to ascertain any differences in AF patterns in these
patients.
The actual incidence of macular dystrophy associated with
the A3243G mutation is probably not known, as most studies,
including ours, have some selection bias based on the clinical
setting from which the patients are ascertained. But certainly
the incidence of macular dystrophy is probably much less
common than the overall incidence of the A3243G mutation
especially given the wide variety of clinical manifestations
associated with this mutation.
Of interest for future study may be genotyping patients
known to have the A3243G point mutation with and without
evidence of macular dystrophy to determine if there is an
increased incidence of genes known to increase AMD risk, such
as complement factor H polymorphisms, in those patients with
macular dystrophy compared with those without.
We conclude that the macular dystrophy associated with the
A3243G mtDNA mutation has a recognizable phenotype by
fundus autofluorescence in most cases and should be considered
in the differential diagnosis, even in the absence of a personal or
family history of diabetes and hearing loss.
Acknowledgements: We are grateful to the patients who kindly agreed to take part
in this study.
Funding: Financial support was from the Foundation Fighting Blindness and the
Moorfields Special Trustees.
Competing interests: None.
Ethics approval: The study was approved by the local Ethics Committee.
REFERENCES
1. van den Ouweland JM, Lemkes HH, Ruitenbeek W, et al. Mutation in mitochondrial
tRNA
Leu(UUR) gene in a large pedigree with maternally transmitted type II diabetes
mellitus and deafness. Nature Genet 1992;1:368–71.
2. Reardon W, Ross RJM, Sweeney MG, et al. Diabetes mellitus associated with a
pathogenic point mutation in mitochondrial DNA. Lancet 1992;340:1376–9.
3. Kobayashi Y, Momoi MY, Tominaga K, et al. A point mutation in the mitochondrial
tRNA(Leu)(UUR0 gene in MELAS (mitochondrial myopathy, encephalopathy, lactic
acidosis and stroke-like episodes). Biochem Biophys Res Commun 1990;173:816–22.
4. Goto Y, Nonaka I, Horai S. A mutation in the tRNA
Leu(UUR) gene associated with the
MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990;348:651–3.
5. Manouvrier S, Ro ¨tig A, Hannebique G, et al. Point mutation of the mitochondrial
tRNA
Leu gene (A 3243 G) in maternally inherited hypertrophic cardiomyopathy,
diabetes mellitus, renal failure, and sensorineural deafness. J Med Genet
1985;32:654–6.
6. Chinnery PF, Howell N, Andrews RM, et al. Clinical mitochondrial genetics. J Med
Genet 1999;36:425–36.
7. Chinnery PF, Howell N, Lightowlers RN, et al. Molecular pathology of MELAS and
MERRF The relationship between mutation load and clinical phenotypes. Brain
1997;120:1713–21.
8. Hammans SR, Sweeney MG, Hanna MG, et al. The mitochondrial DNA transfer
RNALeu(UUR) ARG(3243) mutation. A clinical and genetic study. Brain
1995;118:721–34.
9. Chinnery PF, Howell N, Andrews RM, et al. Mitochondrial DNA analysis:
polymorphisms and pathogenicity. J Med Genet 1999;36:505–10.
10. Mullie MA, Harding AE, Petty RKH, et al. The retinal manifestations of mitochondrial
myopathy. Arch Ophthalmol 1985;103:1825–30.
11. Massin P, Guillausseau P, Bialettes B, et al. Macular pattern dystrophy associated
with a mutation of mitochondrial DNA. Am J Ophthalmol 1995;120:247–8.
Figure 9 (A, B) AF images of a subject
with the peripherin R172W mutation
showing a diffuse speckled abnormality in
macular autofluorescence, with a large
well-demarcated central area of atrophy
associated with reduced AF. Patient
consent has been obtained for publication
of this figure.
Clinical science
628 Br J Ophthalmol 2008;92:623–629. doi:10.1136/bjo.2007.13117712. Massin P, Virally-Monod M, Bialettes B, et al. Prevalence of macular pattern
dystrophy in maternally inherited diabetes and deafness. Ophthalmology
1999;106:1821–7.
13. Isashiki Y, Nakagawa M, Ohba N, et al. Acta Ophthalmol Scand 1998;76:6–13.
14. Harrison TJ, Boles RG, Johnson DR, et al. Macular pattern retinal dystrophy, adult-
onset diabetes, and deafness: A family study of A3243G mitochondrial heteroplasmy.
Am J Ophthalmol 1997;124:217–21.
15. Bonte CA, Matthijs GL, Cassiman JJ, et al. Macular pattern dystrophy in patients
with deafness and diabetes. Retina 1997;17:216–21.
16. Andrews RM, McNeela BJ, Reading P, et al. Mitochondrial DNA disease
masquerading as age-related macular degeneration. Eye 1999;13:595–6.
17. Latkany P, Ciulla TA, Cucchillo P, et al. Mitochondrial maculopathy: geographic
atrophy of the macula in the MELAS associated A to G 3243 mitochondrial DNA point
mutation. Am J Ophthalmol 1999;128:112–14.
18. Smith PR, Bain SC, Good PA, et al. Pigmentary retinal dystrophy and the syndrome of
maternally inherited diabetes and deafness caused by the mitochondrial DNA 3243
tRNA
Leu A to G mutation. Ophthalmology 1999;106:1101–8.
19. von Ru ¨ckmann A, Fitzke FW, Bird AC. In vivo fundus autofluorescence in macular
dystrophies. Arch Ophthalmol 1997;115:609–15.
20. Holz FG, Bellmann C, Margaritidis M, et al. Patterns of increased in vivo fundus
autofluorescence in the junctional zone of geographic atrophy of the retinal pigment
epithelium associated with age-related macular degeneration. Graefes Arch Clin Exp
Ophthalmol 1999;237:145–52.
21. Downes SM, Fitzke FW, Holder GE, et al. Clinical features of codon 172 RDS
macular dystrophy. Similar phenotype in 12 families. Arch Ophthalmol
1999;117:1373–83.
22. Downes SM, Holder GE, Fitzke FW, et al. Autosomal dominant cone and cone–rod
dystrophy with mutations in the guanylate cyclase activator 1A gene-encoding
guanylate cyclase activating protein-1. Arch Ophthalmol 2001;119:96–105.
23. Lois N, Holder GE, Bunce C, et al. Phenotypic subtypes of Stargardt macular
dystrophy-fundus flavimaculatus. Arch Ophthalmol 2001;119:359–69.
24. Bellmann C, Jorzik J, Spital G, et al. Symmetry of bilateral lesions in geographic
atrophy in patients with age-related macular degeneration. Arch Ophthalmol
2002;120:579–84.
25. Kurz-Levin MM, Halfyard AS, Bunce C, et al. Clinical variations in assessment of
bull’s-eye maculopathy. Arch Ophthalmol 2002;120:567–75.
26. Hammans SR, Sweeney MG, Brockington M, et al. Mitochondrial encephalopathies:
molecular genetic diagnosis from blood samples. Lancet 1991;337:1311–13.
27. von Ru ¨ckmann A, Fitzke FW, Bird AC. Distribution of fundus autofluorescence with
a scanning laser ophthalmoscope. Br J Ophthalmol 1995;79:407–12.
28. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus. Diabetes Care 2003;26:5–20S.
29. Guillausseau P, Massin P, Dubois-LaForgue D, et al. Maternally inherited diabetes
and deafness: A multicenter Study. Ann Int Med 2001;134:721–8.
30. Vionnet N, Passa P, Froguel P. Prevalence of mitochondrial gene mutations in
families with diabetes mellitus. Lancet 1993;342:1429–30.
31. Newkirk JE, Taylor RW, Howell N, et al. Maternally inherited diabetes and deafness:
prevalence in a hospital diabetic population. Diabetic Med 1997;14:457–60.
32. Kadowaki T, Kadowaki H, Mori Y, et al. A subtype of diabetes mellitus associated
with a mutation of mitochondrial DNA. NEJM 1994;330:962–8.
33. Kishimoto M, Hashiramoto M, Araki S, et al. Diabetes mellitus carrying a mutation in
the mitochondrial tRNA
Leu(UUR) gene. Diabetologia 1995;38:193–200.
34. Saker PJ, Hattersley AT, Barrow B, et al. UKPDS 21: Low prevalence of the
mitochondrial transfer RNA gene (tRNA
Leu(UUR)) mutation at position 3243bp in UK
caucasian type 2 diabetic patients. Diabetic Med 1997;14:42–5.
35. t’Hart LM, Lemkes HHPJ, Heine RJ, et al. Prevalence of maternally inherited diabetes
and deafness in diabetic populations in the Netherlands. Diabetologia 1994;37:1169–
70.
36. Holmes-Walker DJ, Boyages SC. Prevalence of maternally inherited diabetes and
deafness in Australian diabetic subjects. Diabetologia 1999;42:1028–32.
37. Otabe S, Sakura H, Shimokawa K, et al. The high prevalence of the diabetic patients
with a mutation in the mitochondrial gene in Japan. J Clin Endocrinol Metab
1994;79:768–71.
38. Lehto M, Wipemo C, Ivarsson S-A, et al. High frequency of mutation in MODY and
mitochondrial genes in Scandinavian patients with familial early-onset diabetes.
Diabetologia 1999;42:1131–7.
39. Morgan-Hughes JA, Sweeney MG, Cooper JM, et al. Mitochondrial DNA (mtDNA)
diseases: correlation of genotype to phenotype. Biochim Biophys Acta
1995;1271:135–40.
40. Deschauer M, Wieser T, Neudecker S, et al. Mitochondrial 3243 A G mutation
(MELAS mutation) associated with painful muscle stiffness. Neuromusc Disord
1999;9:305–7.
41. Chinnery PF, Brown DT, Archibald K, et al. Spinocerebellar ataxia and the A3243G
and A8344G mtDNA mutations. J Med Genet 2002;39:e22.
Stay a step ahead with Online First
We publish all our original articles online before they appear in a print issue. This means that the latest
clinical research papers go straight from acceptance to your browser, keeping you at the cutting edge
of medicine. We update the site weekly so that it remains as topical as possible. Follow the Online First
link on the home page and read the latest research.
Clinical science
Br J Ophthalmol 2008;92:623–629. doi:10.1136/bjo.2007.131177 629